Clinical Trial Update: Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Balugrastim (Neugranin) in breast cancer patients receiving doxorubicin/docetaxel; Phase 2/3 completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Neutropenia

Drugs mentioned

• Balugrastim (Balugrastim)
• Neugranin (Neugranin)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chemotherapy-induced Neutropenia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-02-03